Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

ChemoCentryx stock

CCXI
US16383L1061
A0NBM2

Price

51.99
Today +/-
+0
Today %
+0 %

ChemoCentryx stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ChemoCentryx stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ChemoCentryx stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ChemoCentryx stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ChemoCentryx's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ChemoCentryx Stock Price History

DateChemoCentryx Price
10/20/202251.99 undefined
10/19/202251.99 undefined

ChemoCentryx Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ChemoCentryx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ChemoCentryx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ChemoCentryx’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ChemoCentryx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ChemoCentryx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ChemoCentryx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ChemoCentryx’s growth potential.

ChemoCentryx Revenue, EBIT and net profit per share

DateChemoCentryx RevenueChemoCentryx EBITChemoCentryx Net Income
2026e1.3 B undefined885.83 M undefined666.74 M undefined
2025e841.57 M undefined354.33 M undefined266.7 M undefined
2024e412.67 M undefined144.57 M undefined108.81 M undefined
2023e224.88 M undefined-15.02 M undefined-16.13 M undefined
2022e73.85 M undefined-122.73 M undefined-121.79 M undefined
202132.22 M undefined-129.92 M undefined-131.76 M undefined
202064.89 M undefined-55.18 M undefined-55.36 M undefined
201936.13 M undefined-58.3 M undefined-55.49 M undefined
201842.88 M undefined-40.27 M undefined-37.97 M undefined
201782.5 M undefined16.49 M undefined17.86 M undefined
201611.94 M undefined-40.72 M undefined-39.96 M undefined
20150 undefined-47.69 M undefined-47.31 M undefined
20140 undefined-47.4 M undefined-46.93 M undefined
20136.06 M undefined-39.12 M undefined-38.67 M undefined
20125.42 M undefined-39.63 M undefined-39.89 M undefined
201131.67 M undefined-4.3 M undefined-4.62 M undefined
201034.86 M undefined-5.96 M undefined-3.1 M undefined
200949.74 M undefined15.7 M undefined15.62 M undefined
200824.09 M undefined-20.13 M undefined-18.47 M undefined
200720.74 M undefined-19.14 M undefined-15.69 M undefined
20068.11 M undefined-19.14 M undefined-17.34 M undefined

ChemoCentryx Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20062007200820092010201120122013201420152016201720182019202020212022e2023e2024e2025e2026e
0.010.020.020.050.030.030.010.01000.010.080.040.040.060.030.070.220.410.841.3
-150.0020.00104.17-30.61-8.82-83.8720.00---645.45-48.78-14.2977.78-50.00128.13206.8583.93104.1354.10
387.50155.00129.1763.2791.18100.00620.00516.67--281.8237.8073.8186.1148.4496.8842.4713.847.523.692.39
0000000000000003100000
-17-15-1815-3-4-39-38-46-47-3917-37-55-55-131-121-16108266666
--11.7620.00-183.33-120.0033.33875.00-2.5621.052.17-17.02-143.59-317.6548.65-138.18-7.63-86.78-775.00146.30150.38
35.2535.2535.2535.2535.2535.2535.4140.9243.2843.8946.4349.6249.8156.965.6969.8500000
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The ChemoCentryx Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ChemoCentryx is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2009201020112012201320142015201620172018201920202021
                         
57.181.689.5102.7133.373.471.3117.8127.3177172.8436.6264.49
35.412.50.51.20.40030.251.12.10.20.20.45
0000000000000
000000000000851
10.61.30.60.610.80.71.42.31.44.83.38
93.594.791.3104.5134.374.472.1148.7179.8181.4174.4441.6269.18
1.62.11.51.41.41.20.90.91.21.53.952.157.08
8.21.36.616.316.641.3567.9029.523.897.86
0000000000000
0000000000000
0000000000000
0.20.22.10.20.20.20.20.30.40.41.41.51.54
103.610.217.918.242.76.17.29.51.934.877.4156.48
103.598.3101.5122.4152.5117.178.2155.9189.3183.3209.2519425.65
                         
00000000010010010070
163.9166.3170.3244.5318.1328.4339.6357368.6389.4495.6870.8903.65
-86.6-89.7-94.3-134.2-172.9-219.8-267.1-307.1-289.2-374.5-430-485.3-617.1
0100000-100-100-100-100-200300100-499
0000000000000
77.376.776110.3145.2108.572.449.879.314.866385.7286.12
10.90.50.80.90.70.70.71.411.512.96.75
6.274.76.35.67.24.48.27.612.218.719.826.36
6.83.63.63.800.30.529.42451.338.812.610.99
0000000000000
0.40.30.50.50.30000006.318.92
14.411.89.311.46.88.25.638.33364.55951.663.02
00.911.40.400004.719.719.818.14.72
0000000000000
11.88.54.80.30.20.20.267.672.484.564.263.671.8
11.89.416.20.70.20.20.267.677.1104.28481.776.52
26.221.225.512.178.45.8105.9110.1168.7143133.3139.53
103.597.9101.5122.4152.2116.978.2155.7189.4183.5209519425.65
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ChemoCentryx provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ChemoCentryx's financial health and stability.

Assets

ChemoCentryx's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ChemoCentryx must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ChemoCentryx after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ChemoCentryx's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20082009201020112012201320142015201620172018201920202021
-1815-3-4-39-38-46-47-3917-37-55-55-131
00000000000103
00000000000000
-5-411720-31-270-2244-26-5216
012378109889102636
00000000000112
00000000000000
-22-22172-32-33-34-3939416-70-81-75
00-1000000000-15-19
23-29-2714-56-313833-4815-53-12-28292
24-29-2614-56-313834-4816-52-11-266111
00000000000000
000100000041404-1
48-1015767228310963557
47-10115766128724943561
------------1.00-3.00-5.00
00000000000000
48-54-928-3115-3028-1112-617
-23.15-23.1816.471.88-32.7-33.87-34.67-39.5538.854.1615.6-70.91-96.55-94.64
00000000000000

ChemoCentryx stock margins

The ChemoCentryx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ChemoCentryx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ChemoCentryx.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ChemoCentryx's sales revenue. A higher gross margin percentage indicates that the ChemoCentryx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ChemoCentryx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ChemoCentryx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ChemoCentryx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ChemoCentryx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ChemoCentryx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ChemoCentryx Margin History

ChemoCentryx Gross marginChemoCentryx Profit marginChemoCentryx EBIT marginChemoCentryx Profit margin
2026e99.06 %68.35 %51.45 %
2025e99.06 %42.1 %31.69 %
2024e99.06 %35.03 %26.37 %
2023e99.06 %-6.68 %-7.17 %
2022e99.06 %-166.21 %-164.93 %
202199.06 %-403.17 %-408.87 %
202099.06 %-85.04 %-85.31 %
201999.06 %-161.36 %-153.58 %
201899.06 %-93.91 %-88.55 %
201799.06 %19.99 %21.65 %
201699.06 %-341.04 %-334.67 %
201599.06 %0 %0 %
201499.06 %0 %0 %
201399.06 %-645.54 %-638.12 %
201299.06 %-731.18 %-735.98 %
201199.06 %-13.58 %-14.59 %
201099.06 %-17.1 %-8.89 %
200999.06 %31.56 %31.4 %
200899.06 %-83.56 %-76.67 %
200799.06 %-92.29 %-75.65 %
200699.06 %-236 %-213.81 %

ChemoCentryx Stock Sales Revenue, EBIT, Earnings per Share

The ChemoCentryx earnings per share therefore indicates how much revenue ChemoCentryx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ChemoCentryx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ChemoCentryx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ChemoCentryx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ChemoCentryx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ChemoCentryx Revenue, EBIT and net profit per share

DateChemoCentryx Sales per ShareChemoCentryx EBIT per shareChemoCentryx Earnings per Share
2026e18.16 undefined0 undefined9.34 undefined
2025e11.79 undefined0 undefined3.74 undefined
2024e5.78 undefined0 undefined1.52 undefined
2023e3.15 undefined0 undefined-0.23 undefined
2022e1.03 undefined0 undefined-1.71 undefined
20210.46 undefined-1.86 undefined-1.89 undefined
20200.99 undefined-0.84 undefined-0.84 undefined
20190.63 undefined-1.02 undefined-0.98 undefined
20180.86 undefined-0.81 undefined-0.76 undefined
20171.66 undefined0.33 undefined0.36 undefined
20160.26 undefined-0.88 undefined-0.86 undefined
20150 undefined-1.09 undefined-1.08 undefined
20140 undefined-1.1 undefined-1.08 undefined
20130.15 undefined-0.96 undefined-0.95 undefined
20120.15 undefined-1.12 undefined-1.13 undefined
20110.9 undefined-0.12 undefined-0.13 undefined
20100.99 undefined-0.17 undefined-0.09 undefined
20091.41 undefined0.45 undefined0.44 undefined
20080.68 undefined-0.57 undefined-0.52 undefined
20070.59 undefined-0.54 undefined-0.45 undefined
20060.23 undefined-0.54 undefined-0.49 undefined

ChemoCentryx business model

ChemoCentryx Inc. was founded in 1997 and is based in Mountain View, California. The company specializes in the development of medications for rare autoimmune diseases, cancer, and inflammation. Since its founding, ChemoCentryx Inc. has developed a variety of drug candidates, some of which are in clinical phases or as finished products. The business model of ChemoCentryx Inc. is based on the discovery and development of medications targeting chemokines and chemokine receptors. This technology allows for the regulation and control of inflammatory processes. The company also utilizes its proprietary Janus kinase inhibitors (JAK inhibitors) for the treatment of inflammatory diseases. ChemoCentryx Inc. has several business areas. The primary area is the research and development of medications that can be used as candidates against inflammatory, cancer, autoimmune, and fibrosis diseases. The second significant area is collaboration with international partners in the research and development of these medications. The company has also developed specialized tools and technologies to optimize its drug development processes. These techniques include high-throughput screening and X-ray crystallography technologies, as well as biomarker-based diagnostics. One important product of ChemoCentryx Inc. is Avacopan, an oral medication used in the treatment of ANCA-associated vasculitic diseases such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Avacopan is a selective antagonist of the C5a receptor, which plays a central role in the inflammatory response. Clinical studies on the efficacy and safety of Avacopan have yielded promising results, and the medication has received Breakthrough Therapy Designation status from the US FDA. Additionally, ChemoCentryx Inc. has successfully identified candidates for the treatment of atopic dermatitis, lupus nephritis, and Crohn's disease. These products are still in the clinical development phase and have great potential to significantly improve the lives of patients suffering from these conditions. Overall, ChemoCentryx Inc. has made significant progress in the discovery and development of drugs that can combat inflammation and other chronic diseases. The company is well-positioned to expand its pipeline and bring additional breakthrough products to market that will play a crucial role in treating diseases that have been difficult to treat in the past. ChemoCentryx is one of the most popular companies on Eulerpool.com.

ChemoCentryx SWOT Analysis

Strengths

ChemoCentryx Inc possesses several key strengths that contribute to its competitive advantage and success in the pharmaceutical industry:

  • Strong R&D capabilities in developing innovative drugs
  • A robust pipeline of novel drug candidates
  • Well-established strategic partnerships with leading pharmaceutical companies
  • A talented and experienced research team
  • Positive brand reputation and recognition within the industry

Weaknesses

Despite its strengths, ChemoCentryx Inc also faces certain weaknesses that pose challenges to its growth and sustainability:

  • Reliance on external funding for research and development activities
  • Highly competitive market with potential threats from generic drug manufacturers
  • Limited global market reach and geographical presence
  • Potential regulatory hurdles and stringent approval processes
  • Vulnerability to market fluctuations and economic uncertainties

Opportunities

ChemoCentryx Inc can capitalize on the following opportunities to expand its market presence and achieve further growth:

  • Rising demand for targeted and personalized therapies
  • Increasing prevalence of diseases requiring innovative treatment options
  • Emerging markets with unmet medical needs
  • Potential advancements in technology to enhance drug discovery and development
  • Strategic collaborations and partnerships to tap into new markets

Threats

ChemoCentryx Inc should be aware of the following threats that could hinder its growth and market position:

  • Intense competition from established pharmaceutical companies
  • Evolving regulatory landscape and potential changes in healthcare policies
  • Uncertainties in the outcome of clinical trials and drug development
  • Intellectual property challenges and the risk of patent infringement
  • Potential adverse effects of global economic downturns on pharmaceutical spending
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ChemoCentryx Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ChemoCentryx historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

ChemoCentryx shares outstanding

The number of shares was ChemoCentryx in 2023 — This indicates how many shares 69.851 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ChemoCentryx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ChemoCentryx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ChemoCentryx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ChemoCentryx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for ChemoCentryx.

ChemoCentryx shareholders

%
Name
Stocks
Change
Date
14.96499 % Fidelity Management & Research Company LLC10,678,61248,9516/30/2022
8.13684 % The Vanguard Group, Inc.5,806,227686,9126/30/2022
7.27898 % Vifor (International), Ltd5,194,08509/13/2022
5.73376 % BlackRock Institutional Trust Company, N.A.4,091,453306,6036/30/2022
5.67001 % State Street Global Advisors (US)4,045,964404,3016/30/2022
3.35404 % Schall (Thomas J)2,393,35209/13/2022
3.32502 % Pictet Asset Management Ltd.2,372,645532,4786/30/2022
2.94707 % Wasatch Global Investors Inc2,102,9531,027,2316/30/2022
2.51223 % Baker Bros. Advisors LP1,792,657875,7956/30/2022
2.15378 % GW&K Investment Management, LLC1,536,877375,5306/30/2022
1
2
3
4
5
...
10

ChemoCentryx Executives and Management Board

Dr. Thomas Schall

(62)
ChemoCentryx Chairman of the Board, President, Chief Executive Officer (since 1997)
Compensation 8.98 M

Mr. Tausif Butt

(56)
ChemoCentryx Chief Operating Officer, Executive Vice President
Compensation 5.86 M

Ms. Susan Kanaya

(59)
ChemoCentryx Chief Financial and Administrative Officer, Executive Vice President, Secretary, Director (since 2006)
Compensation 3.93 M

Dr. Markus Cappel

(61)
ChemoCentryx Chief Business Officer, Treasurer
Compensation 2.56 M

Dr. Rita Jain

(59)
ChemoCentryx Executive Vice President, Chief Medical Officer, Director (since 2019)
Compensation 1.04 M
1
2
3

ChemoCentryx Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,930,490,550,760,80-0,48
Vifor Pharma Stock
Vifor Pharma
SupplierCustomer0,040,26-0,66-0,620,03-0,33
1

Most common questions regarding ChemoCentryx

What values and corporate philosophy does ChemoCentryx represent?

ChemoCentryx Inc represents a strong commitment to scientific innovation, a focus on patient needs, and a dedication to improving the lives of individuals with serious diseases. The company's corporate philosophy revolves around developing novel therapies that target the chemokine system, aiming to address unmet medical needs. With their extensive research and development efforts, ChemoCentryx Inc aims to provide effective treatments in areas such as autoimmune diseases, cancer, and inflammatory disorders. By leveraging their expertise in chemokine biology, they strive to make a positive impact on patient outcomes and contribute to the advancement of healthcare.

In which countries and regions is ChemoCentryx primarily present?

ChemoCentryx Inc has a primary presence in various countries and regions. The company operates primarily in the United States, where its headquarters is located. Additionally, ChemoCentryx Inc maintains a strong presence in other parts of North America. It also extends its reach to Europe, including countries like Germany, France, and the United Kingdom. Furthermore, ChemoCentryx Inc has a growing presence in Asia, with a focus on countries such as China and Japan. With its global presence, the company is strategically positioned to serve and expand its customer base in these key markets.

What significant milestones has the company ChemoCentryx achieved?

Some significant milestones achieved by ChemoCentryx Inc include the successful completion of multiple clinical trials for their drug candidates, obtaining regulatory approvals for specific treatments, and securing partnerships with other pharmaceutical companies. Additionally, ChemoCentryx Inc has demonstrated positive results in improving patient outcomes and quality of life through their innovative therapies. Notable milestones also include the company's growth and expansion in the pharmaceutical industry, as well as their commitment to advancing research and development efforts in the field of inflammatory and autoimmune diseases.

What is the history and background of the company ChemoCentryx?

ChemoCentryx Inc is a biopharmaceutical company with a rich history and background. Founded in 1997, the company is focused on developing innovative solutions for inflammatory and autoimmune diseases. ChemoCentryx has established itself as a leader in the field of chemokine-based therapeutics, leveraging its deep understanding of the chemokine system to discover and develop potent drugs. Over the years, ChemoCentryx has successfully advanced multiple clinical programs, earning recognition for its groundbreaking research in the treatment of various conditions including rare renal diseases and immune-mediated disorders. With a dedicated team of experts and a commitment to improving patient lives, ChemoCentryx continues to make significant contributions to the pharmaceutical industry.

Who are the main competitors of ChemoCentryx in the market?

The main competitors of ChemoCentryx Inc in the market include top pharmaceutical companies such as Pfizer, Inc., Novartis AG, and AstraZeneca PLC. These companies specialize in the development and commercialization of innovative drugs and therapies in various therapeutic areas, including immunology and inflammation. ChemoCentryx Inc aims to differentiate itself by focusing on the discovery and development of new medications targeting specific chemokine and chemoattractant receptors. Through its unique approach and collaborative efforts with research partners, ChemoCentryx Inc strives to create effective treatments for patients with rare and serious diseases.

In which industries is ChemoCentryx primarily active?

ChemoCentryx Inc is primarily active in the biotechnology industry.

What is the business model of ChemoCentryx?

ChemoCentryx Inc is a biopharmaceutical company with a business model that focuses on the discovery, development, and commercialization of orally-administered medicines. The company primarily aims to develop treatments for immune-inflammatory diseases, autoimmune disorders, and cancer. ChemoCentryx Inc is known for its expertise in targeting the chemokine system, a network of molecules involved in various inflammatory processes. Through its research and development efforts, the company strives to deliver innovative therapies that address unmet medical needs and improve patients' lives. ChemoCentryx Inc's business model centers around advancing its pipeline of drug candidates and partnering with pharmaceutical companies to bring these potential treatments to market.

What is the P/E ratio of ChemoCentryx 2024?

The ChemoCentryx P/E ratio is 33.37.

What is the P/S ratio of ChemoCentryx 2024?

The ChemoCentryx P/S ratio is 8.8.

What is the Quality Investing of ChemoCentryx?

The Quality Investing for ChemoCentryx is 4/10.

What is the revenue of ChemoCentryx 2024?

The expected ChemoCentryx revenue is 412.67 M USD.

How high is the profit of ChemoCentryx 2024?

The expected ChemoCentryx profit is 108.81 M USD.

What is the business model of ChemoCentryx

ChemoCentryx Inc. is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of autoimmune diseases, inflammation, and cancer. It was founded in California in 1997 and is currently headquartered in San Carlos. The company's business model includes research and development of new drugs, focusing on the identification and study of chemokines involved in various diseases. These chemokines are targeted to achieve therapeutic effects. An example of such a drug is Avacopan, currently in Phase III clinical trials for the treatment of ANCA-associated vasculitis (AAV), a rare autoimmune disease causing inflammation in small blood vessels. Avacopan aims to block the chemokine receptor C5a, which triggers the inflammatory response. ChemoCentryx also forms partnerships with other companies in the pharmaceutical industry to advance its research and development, such as the collaboration with Vifor Pharma for the development and marketing of Avacopan in Europe. In addition to research and development, ChemoCentryx has a clinical development department conducting clinical trials to assess the efficacy and safety of its developed drugs and prepare for FDA or EMA approval. Intellectual property protection is also an important aspect of ChemoCentryx's business model, with several patents on its technologies and drugs to prevent imitation. Overall, ChemoCentryx has a promising business model based on discovering and developing innovative drugs for the treatment of severe diseases. Its goal, supported by a secure financial base and dedicated employees, is to continue developing medications that contribute to improving patients' health.

What is the ChemoCentryx dividend?

ChemoCentryx pays a dividend of 0 USD distributed over payouts per year.

How often does ChemoCentryx pay dividends?

The dividend cannot currently be calculated for ChemoCentryx or the company does not pay out a dividend.

What is the ChemoCentryx ISIN?

The ISIN of ChemoCentryx is US16383L1061.

What is the ChemoCentryx WKN?

The WKN of ChemoCentryx is A0NBM2.

What is the ChemoCentryx ticker?

The ticker of ChemoCentryx is CCXI.

How much dividend does ChemoCentryx pay?

Over the past 12 months, ChemoCentryx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ChemoCentryx is expected to pay a dividend of 0 USD.

What is the dividend yield of ChemoCentryx?

The current dividend yield of ChemoCentryx is .

When does ChemoCentryx pay dividends?

ChemoCentryx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ChemoCentryx?

ChemoCentryx paid dividends every year for the past 0 years.

What is the dividend of ChemoCentryx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ChemoCentryx located?

ChemoCentryx is assigned to the 'Health' sector.

Wann musste ich die Aktien von ChemoCentryx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ChemoCentryx from 12/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/2/2024.

When did ChemoCentryx pay the last dividend?

The last dividend was paid out on 12/2/2024.

What was the dividend of ChemoCentryx in the year 2023?

In the year 2023, ChemoCentryx distributed 0 USD as dividends.

In which currency does ChemoCentryx pay out the dividend?

The dividends of ChemoCentryx are distributed in USD.

All fundamentals about ChemoCentryx

Our stock analysis for ChemoCentryx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ChemoCentryx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.